| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 2,169 | 1,804 | 1,222 | 1,141 |
| Research and development | 6,535 | 7,498 | 9,512 | 13,785 |
| General and administrative | 3,337 | 3,516 | 3,825 | 3,799 |
| Restructuring charges | 0 | 0 | - | - |
| Total operating expense | 9,872 | 11,014 | 13,337 | 17,584 |
| Loss from operations | -7,703 | -9,210 | -12,115 | -16,443 |
| Interest income, net | 477 | 599 | 1,053 | 1,267 |
| Other income | 82 | 50 | 22 | - |
| Total other income, net | 559 | 649 | 1,075 | 1,267 |
| Net loss | -7,144 | -8,561 | -11,040 | -15,176 |
| Net unrealized (loss) gain on marketable securities | -4 | -46 | -57 | 249 |
| Comprehensive loss | -7,148 | -8,607 | -11,097 | -14,927 |
| Earnings per share, basic, total | -3.72 | -4.46 | -0.29 | -0.4 |
| Earnings per share, diluted, total | -3.72 | -4.46 | -0.29 | -0.4 |
| Weighted average common shares outstanding - basic | 1,919,441 | 1,917,629 | 38,339,697 | 38,250,982 |
| Weighted-average shares outstanding, diluted | 1,919,441 | 1,917,629 | 38,339,697 | 38,250,982 |
Bolt Biotherapeutics, Inc. (BOLT)
Bolt Biotherapeutics, Inc. (BOLT)